Cargando...
Circulating tumor cell genomic evolution and hormone therapy outcomes in men with metastatic castration-resistant prostate cancer (mCRPC)
Men with circulating tumor cell (CTC) AR-V7 positive mCRPC have worse outcomes when treated with enzalutamide/abiraterone. However, most men lack CTC AR-V7 detection, and additional predictive-biomarkers are needed. We conducted a retrospective secondary analysis of the prospective PROPHECY trial (N...
Gardado en:
| Publicado en: | Mol Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8178231/ https://ncbi.nlm.nih.gov/pubmed/33771885 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1541-7786.MCR-20-0975 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|